SEC Form 8-K Summary
Registrant: Rosecliff Acquisition Corp I; event date: September 6, 2023. The filing relates to Rosecliff’s proposed business combination with Spectral MD Holdings, Ltd., which is associated with Spectral AI. This is a transaction and stockholder-vote filing, not an operating or earnings report.
Business Context and Reporting Period
Rosecliff reported the results of a special stockholder meeting held on September 6, 2023. The proposed transaction involves a two-step merger intended to result in Spectral becoming a wholly owned subsidiary of Rosecliff, with the combined company expected to operate as the post-business-combination entity.
The parties also amended the proposed registration rights and lock-up agreement. The revised lock-up period ends when Rosecliff common stock trades at or above $12.50 per share for 10 trading days within any 30-trading-day period after closing, or 180 days after closing, if earlier.
Key Financial and Transaction Metrics
- Trust account: Approximately $2,571,866.08 remained as of September 6, 2023.
- Redemptions: Holders of 211,136 Class A shares, or approximately 46.02% of outstanding Class A shares, elected to redeem their shares. Redemptions could be revoked before closing.
- Meeting participation: Holders of 6,362,462 shares, representing approximately 93.79% of shares outstanding and entitled to vote as of the August 8, 2023 record date, were present or represented by proxy.
- Revenue, profit, cash flow, margins, debt and liquidity: The filing does not provide operating financial statements or clear values for these metrics. The trust-account balance is the principal liquidity figure disclosed.
Stockholder Vote and Material Changes
| Proposal | For | Against | Abstain | Result |
|---|---|---|---|---|
| Business combination | 6,341,342 | 15,120 | 6,000 | Approved |
| Nasdaq share issuance | 6,339,486 | 16,776 | 6,200 | Approved |
| Amended and restated charter | 6,340,338 | 16,124 | 6,000 | Approved |
| Governance provisions | 6,340,854 | 15,608 | 6,000 | Approved |
| Election of six directors | 6,341,173 | 15,121 | 6,168 | Approved |
| Meeting adjournment | 6,340,339 | 16,123 | 6,000 | Approved |
The business combination was approved by stockholders. Closing was expected on or before September 11, 2023, subject to satisfaction or waiver of applicable closing conditions, unless the parties agreed otherwise.
Outlook, Risks and Unusual Items
- The transaction remained subject to closing conditions, potential changes in redemption elections and other execution risks.
- Forward-looking matters include completion and timing of the business combination, Nasdaq listing compliance, potential PIPE financing, government contracts, FDA, CE and UKCA regulatory submissions and approvals, product development and clinical indications, and the commercial potential of Spectral’s DeepView technology.
- Risks include regulatory approval and certification delays, dependence on government contracts and future awards, market competition, clinical and product-performance uncertainty, financing uncertainty, intellectual-property matters and the ability to maintain or obtain Nasdaq listing.
- The substantial level of Class A redemptions materially reduced the trust-account proceeds available at the time reported.
Investor Verification Items
- Verify whether the business combination ultimately closed and the exact closing date.
- Confirm final redemption amounts, any revoked elections and the final cash available at closing.
- Review the final merger consideration, capitalization, dilution and any PIPE financing.
- Confirm the combined company’s final name, Nasdaq ticker and listing status.
- Review the amended registration rights and lock-up agreement, including the $12.50 trading-price release condition and 180-day backstop.
- Assess the regulatory, clinical, government-contract and commercialization risks described in the related proxy/prospectus and subsequent filings.